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ABSTRACT
Background and aims People who inject drugs (PWID) are a key population at high risk of hepatitis C virus (HCV) in-
fection. The aim of this study was to delineate the epidemiology of HCV in PWID in the Middle East and North Africa
(MENA). Methods Syntheses of data were conducted on the standardized and systematically assembled databases of
the MENA HCV Epidemiology Synthesis Project, 1989–2018. Random-effects meta-analyses and meta-regressions were
performed. Meta-regression variables included country, study site, year of data collection and year of publication [to assess
trends in HCV antibody prevalence over time], sample size and sampling methodology. Numbers of chronically infected
PWID across MENA were estimated. The Shannon Diversity Index was calculated to assess genotype diversity.
Results Based on 118 HCV antibody prevalence measures, the pooled mean prevalence in PWID for all MENA was
49.3% [95% conﬁdence interval (CI) = 44.4–54.1%]. The country-speciﬁc pooled mean ranged from 21.7% (95%
CI = 4.9–38.6%) in Tunisia to 94.2% (95% CI = 90.8–96.7%) in Libya. An estimated 221704 PWID were chronically
infected, with the largest numbers found in Iran at 68526 and in Pakistan at 46554. Therewas no statistically signiﬁcant
evidence for a decline inHCVantibody prevalence over time. Genotype diversity wasmoderate (Shannon Diversity Index of
1.01 out of 1.95; 52.1%). The pooled mean percentage for each HCV genotype was highest in genotype 3 (42.7%) and in
genotype 1 (35.9%). Conclusion Half of people who inject drugs in theMiddle East and North Africa appear to have ever
been infected with hepatitis C virus, but there are large variations in antibody prevalence among countries. In addition to
> 200000 chronically infected current people who inject drugs, there is an unknown number of people who no longer
inject drugs whomay have acquired hepatitis C virus during past injecting drug use. Harm reduction services must be ex-
panded, and innovative strategies need to be employed to ensure accessibility to hepatitis C virus testing and treatment.
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INTRODUCTION
The Middle East and North Africa (MENA) region is re-
ported to have the highest prevalence of hepatitis C virus
(HCV) infection globally, with approximately 20% of all
chronically infected individuals residing in MENA [1,2].
Chronic HCV infection may lead to several morbidities,
such as liver ﬁbrosis, cancer and cirrhosis [3], placing a
burden on health-care systems [4]. Recent development
of the highly effective direct-acting antivirals (DAA) pro-
vides promising new opportunities in controlling HCV
transmission and its disease burden [5]. As such, a global
target for elimination of HCV infection by 2030 has been
set by the World Health Organization (WHO) [6,7].
HCV is a blood-borne pathogen that is transmitted pre-
dominantly parenterally [3]. As a consequence of practices
such as sharing of needles and/or syringes, people who in-
ject drugs (PWID) are a key population at high risk of HCV
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infection, half of whom are estimated to have been infected
with HCV globally [8]. MENA is particularly vulnerable to
injecting drug use, being at the epicenter of major drug
production sites and trade routes [9,10]. Recent evidence
has suggested that targeting PWID for HCV screening is
critical for program efﬁciency in identifying HCV infections
[11]. A comprehensive characterization of HCV epidemiol-
ogy in PWID in this region is essential to inform the expan-
sion of harm reduction services and development of
population-speciﬁc and cost-effective screening and treat-
ment programs for HCV infection.
The aim of this study was to delineate HCV epidemiol-
ogy among PWID in MENA by: (1) estimating the
country-speciﬁc pooled mean HCV antibody prevalence in
PWID, (2) estimating the country-speciﬁc number of
chronically infected PWID, (3) identifying predictors and
trends of HCV antibody prevalence in PWID as well as
sources of between-study heterogeneity and (4) estimating
the pooled mean proportions and diversity of HCV geno-
types in PWID. This study was conducted as part of the
MENA HCV Epidemiology Synthesis Project [2], an ongo-
ing undertaking to characterize HCVepidemiology and in-
form key public health research, policy and programming
priorities in the region.
METHODS
Data sources
All studies reporting on HCV measures in PWID in MENA
were retrieved from the MENA HCV Epidemiology Synthe-
sis Project database [2]. This comprehensive database
includes several subdatabases, such as an HCV antibody
prevalence subdatabase comprised of 2614 antibody
prevalence studies among 49821739 participants, an
HCV genotype frequency subdatabase comprised of 338
HCV genotype studies among 82257 participants and an
HCV ribonucleic acid (RNA) prevalence (among
antibody-positive people) subdatabase comprised of 179
RNA prevalence studies among 19680 participants.
The Synthesis Project database was developed through
a series of systematic reviews for HCV infection throughout
MENA [12–19]. Additional data in PWID were searched
for by performing a search update of PubMed and Embase,
following similar methodologies to these systematic re-
views [12–19]. In brief, to perform the update, all records
reporting HCV antibody prevalence and/or incidence in
PWID in MENAup to November 2018 were systematically
reviewed and included in this study, as informed by the
Cochrane Collaboration handbook [20], and reported
using the Preferred Reporting Items for Systematic reviews
and Meta-analyses (PRISMA) guidelines (Supporting infor-
mation, Table S1). Broad search criteria with no language
restrictions were used in all these reviews (Supporting
information, Fig. S1) [12–19]. All records reporting HCV
measures after 1989, the year in which existence of
HCV as a virus was established [21,22], were included in
these reviews [12–19].
All data included in the reviews [12–19] were identiﬁed
through literature searches using international databases
(PubMed and Embase), regional and country-level data-
bases (WHO Index Medicus for the Eastern Mediterranean
Region and the Iraqi Academic Scientiﬁc Journals, Iran’s
Scientiﬁc Information, among others), MENA HIV/AIDS
Epidemiology Synthesis Project database [23,24], abstract
archives of non-indexed international conferences and
gray literature comprised of public health reports and rou-
tine data reporting.
Duplicate records were excluded and the remaining
unique records underwent two rounds of screening. The ti-
tles and abstracts were screened for relevance, and full
texts of potentially relevant records were retrieved and fur-
ther screened. References of all included full texts were also
screened for additional data that may have been missed.
Any document reporting primary data on HCV antibody
prevalence and/or incidence was included. All records
were included in an additional independent screening for
HCV genotype information, regardless of whether or not
they had reported HCV antibody prevalence.
In this study, MENA consists of 24 countries:
Afghanistan, Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq,
Jordan, Kuwait, Lebanon, Libya, Mauritania, Morocco,
Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Somalia,
Sudan, Syria, Tunisia, the United Arab Emirates (UAE)
and Yemen.
The analysis in this study was not pre-registered and
the results should be considered exploratory.
Pooled mean HCV antibody prevalence
Country-speciﬁc meta-analyses to pool HCVantibody prev-
alence measures were performed whenever three or more
prevalence measures were available, with a minimum
sample size of 25 participants for each measure. HCVanti-
body prevalence for the total sample was replaced with
stratiﬁed measures if the sample size requirement was held
for each stratum. Only one stratiﬁcation level for each
study was included based on an a priori sequential order
of prioritizing nationality followed by sex, year and age.
All meta-analyses were performed using DerSimonian–
Laird random-effects models with inverse variance
weighting to poolmeasures [25]. Variance of eachmeasure
was stabilized using the Freeman–Tukey-type arcsine
square root transformation [26]. Heterogeneity was char-
acterized using several statistical measures [25,27]. Forest
plots were visually inspected and Cochran’s Q-test was con-
ducted, where a P-value< 0.10was considered to indicate
statistical signiﬁcance [25,27], I2 and its conﬁdence inter-
val (CI) were calculated [25]. Prediction intervals were also
2 Sarwat Mahmud et al.
© 2020 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
calculated to discern the distribution of true effects around
the estimated mean [25,28].
Statistical analyses were performed using R version
3.4.3 [29].
Estimation of number of HCV-infected PWID
The country-speciﬁc number of HCV antibody-positive
PWID was calculated by multiplying the country-speciﬁc
pooled HCV antibody prevalence by the country-speciﬁc
population size of PWID. If the country-speciﬁc pooled
HCV antibody prevalence was unavailable, the pooled
HCV antibody prevalence for MENA as a whole was used.
This was subsequently multiplied by the region’s pooled
mean fraction of HCV RNA positivity among antibody-
positive PWID (i.e. the ‘viremic rate’ [30,31]) to attain
the number of chronically infected PWID in each country
and in MENA as a whole.
The viremic rate was estimated by performing a
meta-analysis of proportion for all HCV RNA positivity
data among antibody-positive PWID in MENA. The
country-speciﬁc population size of PWID was derived from
a systematic review and synthesis in which PWID popula-
tion proportion and population size were extracted and
synthesized from publications in the peer-reviewed litera-
ture, United Nations Ofﬁce on Drugs and Crime (UNODC)
estimates and data provided by the WHO Eastern Mediter-
ranean Regional Ofﬁce (EMRO) [32]. In countries with
multiple population-size estimates, the median of these
estimates was used. The estimates were subsequently
updated with recent data [33–42] identiﬁed through a
data and literature search.
Predictors, trends and sources of between-study
heterogeneity for HCV antibody prevalence
Based on established methodology, [20] univariable and
multivariable random-effects meta-regressions were per-
formed to assess the predictors of HCVantibody prevalence
in PWID, trend in prevalence over time and sources of
between-study heterogeneity. A priori-relevant indepen-
dent variables included country, study site, year of data
collection and year of publication (to assess trend in HCV
antibody prevalence over time), sample size (< 100
or ≥ 100) and sampling method (probability-based versus
non-probability-based). Countries with three or fewer
studies were lumped together as one category referred to
as ‘Others’. Variables with a likelihood ratio test P-value
of < 0.20 in the univariable analysis were included in the
ﬁnal multivariable model. Variables with a P-value of
< 0.05 in the multivariable model were deemed statisti-
cally signiﬁcant.
In studies where the year of data collection variable was
unavailable, missing observations were imputed. This was
performed by using the median of the values calculated
by subtracting the year of data collection from the year of
publication for each study.
Separate meta-regressions were performed in countries
with ≥ 15 studies to assess the trend in HCV antibody
prevalence over time.
Meta-regressions were performed on Stata version 13,
using the metan command [43].
Genotype proportions and diversity
Individuals with untypeable genotypes were removed from
the sample size of each study. Individuals with mixed geno-
types contributed separately to the enumeration of each
genotype. Frequency of each genotype was calculated.
The pooled mean proportion for each genotype and the
corresponding 95% CI were also estimated by performing
random-effects meta-analyses. Diversity of genotypes was
assessed by calculating the Shannon Diversity Index, with
higher score indicating higher diversity [44]. Assuming
highest diversity, i.e. equal distribution among the seven
main genotypes [44], the largest Shannon Diversity Index
score possible is 1.95 [45].
RESULTS
Overview of evidence
Supporting information, Figs S2 and S3 outline the process
by which HCV incidence and/or prevalence studies and
HCV genotype studies were selected in the update, as per
the PRISMA ﬂow diagram. Relative to the previous system-
atic reviews, the update identiﬁed no additional incidence
reports, 10 additional prevalence reports and one addi-
tional genotype report.
Results using all searches combined were generated
based on analysis of 118 HCV antibody measures among
a total of 46493 PWID (Table 1), seven HCV RNA positiv-
ity measures among a total of 920 antibody-positive PWID
(Supporting information, Table S2) and 15 genotype fre-
quency measures among a total of 969 HCV RNA-positive
PWID (Supporting information, Table S3).
PWID datawere available for 12 of the 24MENA coun-
tries. No studies were available for Algeria, Bahrain,
Djibouti, Iraq, Jordan, Kuwait, Mauritania, Qatar,
Somalia, Sudan, UAE and Yemen. Iran contributed the
largest number of data points of HCV antibody prevalence
measures (n = 60), followed by Pakistan (n = 19). HCV
RNA positivity measures were available for only four coun-
tries: Afghanistan, Iran, Lebanon and Pakistan. Genotype
frequency measures were available for only seven coun-
tries: Afghanistan, Iran, Lebanon, Morocco, Pakistan and
Saudi Arabia.
Studies identiﬁed their samples from various study sites,
such as in the community (a geographical area, such as a
HCV epidemiology in PWID 3
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Table 1 Studies reporting hepatitis C virus (HCV) antibody prevalence among people who inject drugs (PWID) across the Middle East and
North Africa (MENA).
Author, year (citation)
Year(s) of data
collection Study site
Study
design
Study sampling
procedure
Sample
size
HCVantibody
prevalence (%)
Afghanistan (n = 17)
Afghanistan NACP, 2010 [46] 2009 NS CS RDS 286 37.1
Afghanistan NACP, 2010 [46] 2009 NS CS RDS 159 57.9
Afghanistan NACP, 2010 [46] 2009 NS CS RDS 102 25.5
Afghanistan NACP, 2012 [47] 2012 NS CS RDS 369 27.6
Afghanistan NACP, 2012 [47] 2012 NS CS RDS 185 70.8
Afghanistan NACP, 2012 [47] 2012 NS CS RDS 254 23.6
Afghanistan NACP, 2012 [47] 2012 NS CS RDS 236 15.3
Afghanistan NACP, 2012 [47] 2012 NS CS RDS 117 28.2
Bautista, 2010 [48] 2005–06 VCT CS Conv 153 36.0
Bautista, 2010 [48] 2005–06 VCT CS Conv 159 37.0
Bautista, 2010 [48] 2005–06 VCT CS Conv 147 37.0
MENA HIV Epidemiology Synthesis
Project, 2011 [23,49]
2011 NS CS NS 4866 15.7
Nasir, 2011 [50] 2006–08 VCT CS Conv 340 49.1
Nasir, 2011 [50] 2006–08 VCT CS Conv 96 12.5
Nasir, 2011 [50] 2006–8 VCT CS Conv 187 24.1
Todd, 2007 [51] 2005–06 VCT CS Conv 458 36.9
Todd, 2011 [52] 2007–09 NS CS Conv 483 36.1
Egypt (n = 2)
el-Ghazzawi, 1995 [53] NS NS CC Conv 100 63.0
Mohsen, 2015 [54] 2002–12 Clinical setting CC Conv 143 40.6
Iran (n = 60)
Abadi, 2018 [55] 2013–14 Clinical setting CS Conv 173 53.5
Alavi, 2007 [56] 2001–03 Clinical setting CS Conv 104 74.0
Alavi, 2009 [57] 2001–06 Clinical setting CS Conv 142 52.1
Alipour, 2013 [58] NS Drop-in or
rehabilitation center
CS Conv 42 35.7
Alipour, 2013 [58] NS Drop-in or
rehabilitation center
CS Conv 226 38.1
Alizadeh, 2005 [59] 2002 Prison CS SRS 149 31.5
Amini, 2005 [60] NS Blood transfusion
center
CS Conv 34 64.7
Amiri, 2007 [61] 2003 Prison CS Conv 81 88.9
Asl, 2013 [62] 2003–5 Prison Coha Conv 150 69.3
Ataei, 2010 [63] 2008–09 Drop-in or
rehabilitation center
CS Conv 3284 38.0
Ataei, 2011 [64] NS Prison CS Conv 1485 43.4
Ataei, 2011 [65] NS Drop-in or
rehabilitation center
CS Conv 136 19.9
Davoodian, 2009 [66] 2002 Prison CS SRS 249 65.5
Doosti-Irani, 2017 [67] 2015 Community CS Conv 119 80.7
Eskandarieh, 2013 [68] NS Drop-in or
rehabilitation center
CS Conv 258 65.1
Honarvar, 2013 [69] 2012–13 Drop-in and
rehabilitation centers
CS Conv 233 40.3
Hosseini, 2010 [70] 2006 Prison CS Conv 417 80.1
Imani, 2008 [71] 2004 Drop-in or
rehabilitation center
CS Conv 133 11.3
Ismail, 2005 [72] NS Clinical setting CS Conv 65 16.9
Kaffashian, 2011 [73] NS Prison CS Conv 951 41.9
Kassaian, 2012 [74] 2009 Prison CS Conv 943 41.6
Keramat, 2011 [75] 2005–07 Drop-in or
rehabilitation center
CS Conv 199 63.3
(Continues)
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Table 1. (Continued)
Author, year (citation)
Year(s) of data
collection Study site
Study
design
Study sampling
procedure
Sample
size
HCV antibody
prevalence (%)
Khani, 2003 [76] 2001 Prison CS Conv 346 50.9
Kheirandish, 2009 [77] 2006 Prison CS Conv 61 67.2
Kheirandish, 2009 [77] 2006 Prison CS Conv 229 80.8
Kheirandish, 2009 [77] 2006 Prison CS Conv 103 82.5
Kheirandish, 2009 [77] 2006 Prison CS Conv 49 87.8
Khorvash, 2008 [78] 2005 Clinical setting CS Conv 92 71.0
Mehrjerdi, 2014 [79] 2011 Drop-in or
rehabilitation center
CS Conv 209 26.8
Meydani, 2009 [80] 2007–08 Clinical setting CS Conv 150 26.0
Mirahmadizadeh, 2004 [81] NS NS CS Conv 186 80.1
Mirahmadizadeh, 2009 [82] NS Drop-in or
rehabilitation center
CS SRS 936 43.4
Mir-Nasseri, 2005 [83] 2001–02 Drop-in or
rehabilitation center
CS NS 42 50.0
Mir-Nasseri, 2005 [83] 2001–02 Drop-in or
rehabilitation center
CS NS 425 67.5
Mir-Nasseri, 2008 [84] 2001–02 Drop-in or
rehabilitation center
CS Conv 54 38.9
Mir-Nasseri, 2008 [84] 2001–02 Drop-in or
rehabilitation center
CS Conv 464 61.9
Mir-Nasseri, 2011 [85] 2001–02 Drop-in or
rehabilitation center
CS Conv 518 69.3
Moradi, 2018 [86] 2015 Prison CS Multi-stage
cluster sampling
678 42.5
Momen-Heravi, 2012 [87] NS Drop-in or
rehabilitation center
CS Multi-stage
cluster sampling
300 47.3
Pourahmad, 2007 [88] 2003 Prison CC Conv 401 76.8
Rahbar, 2004 [89] 2001 Prison CC Conv 101 59.4
Rahimi-Movaghar, 2010 [90] 2006–07 Drop-in or
rehabilitation center
CS Snowball
sampling
859 34.1
Rahimi-Movaghar, 2010 [90] 2006–07 Drop-in or
rehabilitation center
CS Snowball
sampling
36 44.4
Ramezani, 2014 [91] 2012 Drop-in or
rehabilitation center
CS Conv 100 56.0
Rostami-Jalilian, 2006 [92] 2002–04 Clinical setting CS Conv 76 34.2
Rostami-Jalilian, 2006 [92] 2002–04 Clinical setting CS Conv 72 45.8
Saleh, 2011 [93] 2007–08 Clinical setting CC Conv 94 60.6
Salehi, 2015 [94] 2006–11 Community CS Conv 1327 13.5
Sarkari, 2012 [96] 2009–10 NS CS Conv 158 42.4
Shahrani, 2017 [97] 2017 Drop-in or
rehabilitation center
CS Snowball
sampling
606 54.8
Sharif, 2009 [98] 2001–06 Clinical setting CS Conv 200 12.0
Shariﬁ-Mood, 2006 [99] 2000–05 Clinical setting CS Conv 31 22.6
Soﬁan, 2012 [100] 2009 Prison CS Conv 153 59.5
Soudbakhsh, 2008 [101] NS Clinical setting CS Conv 26 88.5
Tavanaee, 2012 [95] 2007–09 Clinical setting CS Conv 62 71.0
Tayeri, 2008 [102] 2000–07 Clinical setting CS Conv 106 75.5
Aminzadeh, 2007 [103] 2007 NS CS Conv 70 35.7
Zali, 2001 [104] 1995 Prison CS SRS 402 45.3
Zamani, 2007 [105] 2004 Mixed CS Conv 202 52.0
Zamani, 2010 [106] 2008 Drop-in or
rehabilitation center
CS Snowball
sampling
117 60.7
(Continues)
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Table 1. (Continued)
Author, year (citation)
Year(s) of data
collection Study site
Study
design
Study sampling
procedure
Sample
size
HCVantibody
prevalence (%)
Lebanon (n = 3)
Mahfoud, 2010 [107] 2007–08 NS CS RDS 106 52.8
Merabi, 2016 [108] 2013 Drop-in or
rehabilitation center
CS Conv 94 23.4
Ramia, 2003 [109] NS Clinical setting CS Conv 40 5.0
Libya (n = 1)
Mirzoyan, 2013 [110] 2010–10 Community CS RDS 328 94.2
Morocco (n = 3)
Integrated behavioral and biological
survey, 2012 [111]
NS NS CS RDS 269 45.6
Integrated behavioral and biological
survey, 2012 [111]
NS NS CS RDS 278 79.2
Moroccan Ministry of Health, 2014
[112]
2013–14 NS CS RDS 212 45.4
Oman (n = 1)
EMRO, 2011 [113] NS NS CS Conv 512 48.1
Pakistan (n = 19)
Kuo, 2006 [114] 2003–03 Clinical setting CS Conv 351 88.0
Achakzai, 2007 [115] 2004 Community CS Conv 50 60.0
Altaf, 2007 [116] 2003 Drop-in or
rehabilitation center
CS Conv 161 94.3
Abbasi, 2009 [117] 2003 Community CS Conv 300 44.7
Butt, 2011 [118] NS Prison CS Conv 76 84.2
Platt, 2009 [119] 2007 Community CS RDS 302 17.3
Platt, 2009 [119] 2007 Community CS RDS 102 8.0
Rehan, 2009 [120] 2004 Community CS SRS 399 87.0
Rehan, 2009 [120] 2004 Community CS SRS 380 91.8
Rehman, 2011 [121] NS Community CS Conv 100 35.0
Rehman, 2011 [121] NS Community CS Conv 60 25.0
Rehman, 2011 [121] NS Community CS Conv 40 32.5
Memon, 2012 [122] 2007–08 Laboratory CS Conv 407 68.3
Daud, 2014 [123] 2008 Drop-in or
rehabilitation center
CS Conv 81 77.8
Akhtar, 2016 [124] 2012–13 Community CS Conv 241 36.1
Mansha, 2017 [125] 2013 Laboratory CS Conv 100 55.0
Waheed, 2017 [126] 2016 Community CS Conv 72 83.3
Ali, 2011 [127] NS Mixed CS Conv 42 14.3
Rasool, 2014 [128] 2009 Clinical setting Coha Conv 40 42.0
Palestine (n = 4)
Stulhofer, 2012 [129] 2010 Other CS RDS 192 43.8
Stulhofer, 2016 [130] 2013 NS CS TLS 100 39.0
Stulhofer, 2016 [130] 2013 NS CS TLS 83 33.7
Stulhofer, 2016 [130] 2013 NS CS TLS 105 47.6
Saudi Arabia (n = 5)
Njoh, 1997 [131] 1995–96 Drop-in or
rehabilitation center
CS Conv 1909 74.6
Iqbal, 2000 [132] NS Clinical setting CS Conv 574 69.0
Shobokshi, 2003 [133] 1998–2002 Clinical setting CS Conv 9137 14.4
Alshomrani, 2015 [134] 2006–12 Clinical setting CS Conv 378 77.8
Alibrahim, 2018 [135] 2012 Drop-in or
rehabilitation center
CS Conv 300 42.7
Syria (n = 2)
Syrian Ministry of Health, 2008
[136]
2006 NS CS Snowball
sampling
57 21.0
Othman, 2002 [137] NS NS CS Conv 38 60.5
(Continues)
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city, town, village, etc.), clinical setting (such as a hospital),
drop-in center or rehabilitation center, voluntary counsel-
ling and testing center, prison or were not speciﬁed. The
majority of studies used non-probability-based sampling
(approximately 75%) to recruit study subjects, and had a
sample size ≥ 100 (approximately 70%).
HCV antibody prevalence among PWID
HCV antibody prevalence ranged from 5.0% in a study
from Lebanon [109] to 94.3% in a study from Pakistan
[116] (Table 1). The median HCV antibody prevalence
among all studies was 45.5%, with an interquartile range
of 34.4–67.4%. Table 2 lists the estimated pooledmean an-
tibody prevalence among PWID across MENA. The
country-speciﬁc estimate ranged from 21.7% (95%
CI = 4.9–38.6%) in Tunisia to 94.2% (95% CI = 90.8–
96.7%) in Libya. Egypt, Iran, Libya, Morocco, Pakistan
and Saudi Arabia had a prevalence estimate > 50%. The
pooled mean for MENA as a whole was 49.3% (95%
CI = 44.4–54.1%).
Evidence for heterogeneity in HCVantibody prevalence
was observed in the majority of meta-analyses (P < 0.01;
Table 2). Most of the variation in prevalence was due to
true variation in prevalence across studies rather than
sampling variation (I2 was most often > 90%; Table 2).
This was also conﬁrmed by the wide prediction intervals
(Table 2).
Estimated number of infections among PWID
Based on a total of seven identiﬁed studies (Supporting in-
formation, Table S2), the pooled mean viremic rate was
70.4% (95% CI = 53.7–84.9%). This estimate was used
in calculating the number of chronic infections for each
country and for MENA as a whole.
Table 2 lists the estimated number of HCV antibody-
positive PWID and the estimated number of chronically in-
fected PWID in each country and in MENA as awhole. The
largest number of chronically infected PWID was found in
Iran at 68526, followed by Pakistan at 46554 and Egypt
at 32997. The remaining countries had a substantially
smaller number of chronically infected PWID. In MENA
as a whole, 314831 PWID were estimated to be
antibody-positive and 221704 PWID were estimated to
be chronically infected.
HCVantibody prevalence predictors, trends and sources of
between-study heterogeneity
Table 3 lists the results of the univariable and multivariable
meta-regressions. The variables country, study site and
year of data collection were found to be statistically signiﬁ-
cant predictors (P < 0.2), and were therefore included in
the ﬁnal multivariable analysis.
In the multivariable analysis, year of data collection lost
signiﬁcance (P > 0.05): here, only country and study site
remained statistically signiﬁcant. Pakistan had a statisti-
cally signiﬁcant higher HCV antibody prevalence among
PWID than in Afghanistan; the adjusted OR was 5.0
(95% CI = 1.4–18.0). Prison study site had a statistically
signiﬁcant higher antibody prevalence among PWID
than in the community; the adjusted OR was 2.6 (95%
CI = 1.0–6.7)
Notably, no small-study effect, i.e. studies with smaller
sample size yielding different antibody prevalence, [139]
was found. Similarly, the sampling method had no effect
on observed antibody prevalence. The model explained
7.7% of the variability in antibody prevalence.
Separate meta-regressions were performed for
Afghanistan, Iran and Pakistan (countries with ≥ 15
studies), all of which showed no statistically signiﬁcant
evidence for a declining or increasing trend in antibody
prevalence over time.
A sensitivity analysis was performed using only
the non-imputed observations to assess the impact of the
imputation on the results, and the results conﬁrmed the re-
sults of the original meta-regression.
Genotype proportions and diversity
Table 4 lists the frequency of each HCV genotype as well as
its pooled mean proportion estimate. The pooled mean
proportion (expressed as a percentage) was 42.7% (95%
Table 1. (Continued)
Author, year (citation)
Year(s) of data
collection Study site
Study
design
Study sampling
procedure
Sample
size
HCV antibody
prevalence (%)
Tunisia (n = 1)
Belarbi, 2013 [138] 2012 Clinical setting CS Conv 23 21.7
NACP = National AIDS Control Program; EMRO = Eastern Mediterranean Regional Ofﬁce; NS = not speciﬁed; VCT = voluntary counselling and testing;
CS = cross-sectional; CC = case–control; Coh = cohort; RDS = respondent-driven sampling; Conv = convenience; SRS = simple random sampling;
TLS = time–location sampling. aIn cohort studies the extracted HCVantibody prevalence measure was the cross-sectional baseline HCVantibody prevalence
measure.
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Table 3 Univariable andmultivariable meta-regressionmodels for hepatitis C virus (HCV) antibody prevalence in people who inject drugs
(PWID) across the Middle East and North Africa (MENA).
Univariable analysis Multivariable analysisa
Number of
studies OR (95% CI)
P-
value
LR test P-
value
Variance explained
adj R2 (%) aOR (95% CI)
P-
value
Country Afghanistan 17 1 – 1 –
Iran 60 2.4 (1.3–4.2) 0.004 2.5 (0.8–7.8) 0.109
Pakistan 19 2.8 (1.4–5.8) 0.005 5.0 (1.4–
18.0)
0.014
Palestine 4 1.5 (0.4–4.8) 0.525 1.5 (0.4–5.2) 0.531
Saudi Arabia 5 2.6 (0.9–7.7) 0.084 3.5 (0.8–
15.8)
0.109
Othersb 13 1.7 (0.8–3.8) 0.173 0.054 5.1 2.0 (0.7–5.2) 0.170
Study site Community 14 1 – 1 –
Clinical setting 24 0.8 (0.4–1.7) 0.580 1.2 (0.5–2.7) 0.713
Drop-in or
rehabilitation center
26 0.9 (0.4–1.8) 0.787 1.4 (0.6–3.4) 0.438
VCT 7 0.4 (0.2–1.1) 0.086 1.8 (0.4–8.3) 0.478
Prison 19 1.7 (0.8–3.5) 0.173 2.6 (1.0–6.7) 0.041
Not speciﬁed 25 0.6 (0.3–1.3) 0.223 0.034 6.3 1.9 (0.6–5.7) 0.269
Year of data
collection
118 1.0 (0.9–1.0) 0.188 0.188 0.6 1.0 (0.9–1.0) 0.643
Year of
publication
118 1.0 (0.9–1.0) 0.434 0.434 0.0 – –
Sample size < 100 34 1 – – –
≥ 100 84 1.1 (0.7–1.7) 0.702 0.702 0.0 – –
Sampling
method
Non-probability-
based
91 1 – – –
Probability-based 27 0.9 (0.5–1.4) 0.525 0.525 0.0 – –
Adj=adjusted; CI = conﬁdence interval; LR = likelihood ratio; OR = odds ratio; aOR = adjusted odds ratio; VCT = voluntary counselling and testing. aThe ad-
justed R-squared for the full model was 7.7%. bCountries with three or fewer studies (Egypt, Lebanon, Libya, Morocco, Oman, Syria and Tunisia) were com-
bined into the ‘Others’ category.
Table 4 Frequency and pooled mean proportion for each hepatitis C virus (HCV) genotype across the Middle East and North Africa
(MENA).
Genotype
Studies Samples
Percentage (actual
studies)
Percentage (meta-
analysis) Heterogeneity measures
Total
N n (%)
Median
(%)
Range
(%)
Mean
(%) 95% CI Q (P-value)a I2 (conﬁdence limits)b
Prediction interval
(%)c
Genotype
1
15 449
(46.3%)
41.7 0.0–
64.9
35.9 23.5–
49.1
163.5
(P < 0.01)
91.4% (87.6–94.1%) 0.1–85.9
Genotype
2
15 48 (5.0%) 0.0 0.0–
41.5
0.5 0.0–4.2 85.2
(P < 0.01)
83.6% (74.2–89.5%) 0.0–23.4
Genotype
3
15 422
(43.6%)
50.0 0.0–
100
42.7 31.7–
54.0
114.0
(P < 0.01)
87.7% (81.4–91.9%) 6.2–83.9
Genotype
4
15 47 (4.9%) 27.4 0.0–
75.0
4.1 0.1–
11.7
144.0
(P < 0.01)
90.3% (85.7–93.4%) 0.0–44.7
Genotype
5
15 3 (0.3%) 0.0 0.0–2.9 0.0 0.0–0.0 9.9 (P= 0.77) 0.0% (0.0–0.0%) 0.0–0.0
CI = conﬁdence interval. aQ = Cochran Q statistic assessing the existence of heterogeneity in HCV genotype proportion estimates. bI
2
= A measure assessing
the magnitude of between-study variation that is due to true differences in HCV genotype proportion estimates across studies rather than chance. cPrediction
interval = estimates the 95% interval in which the true HCV genotype proportion estimate in a new HCV genotype study will lie.
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CI = 31.7–54.0%) for genotype 3, 35.9% (95% CI = 23.5–
49.1%) for genotype 1, 4.1% (95%CI = 0.1–11.7%) for ge-
notype 4, 0.5% (95% CI = 0.0–4.2%) for genotype 2 and
0.0% (95% CI = 0.0–0.0%) for genotype 5. Genotypes 6
and 7 were not found (among PWID) in any of the avail-
able studies. Genotype diversity was moderate for MENA
as a whole (Shannon Diversity Index = 1.01 out of 1.95;
52.1%). Most PWID were infected by a single genotype:
only 2.1% of them were coinfected by multiple genotypes.
DISCUSSION
We have presented a comprehensive characterization of
HCV epidemiology among PWID in MENA. Generally, we
found very high HCV antibody prevalence among PWID,
which varied by country. Approximately half (49.3%) of
PWID have ever been infected with HCV, with more than
two-thirds (70.4%) of those ever being infected being
chronically infected—ﬁndings that are similar to the global
epidemiology of HCV in PWID [8,31]. The variables coun-
try (Pakistan, with an OR of 5.0) and study site (prison,
with an ORof 2.6) were identiﬁed as statistically signiﬁcant
predictors of higher antibody prevalence; there was no
evidence that sampling method or sample size affected
the observed prevalence. No evidence was also found for
any change in antibody prevalence over time. Moderate
genotype diversity was observed in MENA as a whole.
The pooled mean percentages of genotypes were highest
in genotype 3 (42.7%), followed by genotype 1 (35.9%).
We estimated that there are approximately 221000
chronically infected PWID in MENA (Table 2). As this esti-
mate is only for those currently injecting, this number rep-
resents the lower bound for the number of chronically
infected people who acquired HCV through injecting drug
use in this region. As available studies normally investigate
PWID who are currently injecting, we are unable to esti-
mate the number of chronic infections among ex-PWID,
people who injected drugs in the past, but are no longer
injecting at present. In the United States, for example,
the number of HCV-infected ex-PWID was found to be
sevenfold higher than that of HCV-infected current PWID.
[140] Therefore, the number of chronic infections due to
injecting drug use in MENA could be substantially greater
than the estimated 221000 for current PWID, although
probably not sevenfold higher as it is in the United
States, as injecting drug use in this region appears to be
more of a recent phenomenon compared to the United
States [2,32].
The identiﬁed very high HCV antibody prevalence, at
49% (Table 2), among PWID indicates that there is high
epidemic potential for concentrated HIV epidemics. A re-
centmathematical modeling study, [141] as well as ecolog-
ical analyses [32,142], suggest that an antibody
prevalence level > 45% indicates an epidemic potential
for sustainable and concentrated HIV epidemics. Indeed,
reviews of the HIV epidemic among PWID in MENA
[9,23,24,32,143], as well as modeling estimates [144–
146], indicate emerging HIV epidemics with often high
levels of infection incidence.
HCV antibody prevalence in PWID varied throughout,
and within, countries (Table 1). In Afghanistan, for exam-
ple, antibody prevalence showed subnational variation
[18]. This variability may be reﬂective of variation in the
local injecting environment, impact of expansion of harm
reduction services [147] or the natural HCV epidemic dy-
namics among recently formed injecting networks.
Variations in antibody prevalence across MENA may
also be attributed to differences in the typologies of the
PWID populations and nature of their social and injecting
networks [23,148]. For example, in Lebanon, where anti-
body prevalence was on the lower range of that observed
in MENA, PWID appear to form closed small networks,
with most injecting occurring in private residences and
among friends [2,32,149], and thus not conducive for
HCV (or HIV) transmission. In contrast, in Iran and
Pakistan, where antibody prevalence was in the higher
range of that observed in MENA, PWID networks appear
to be well connected, with instances of injecting occurring
among individuals not necessarily socially related, such as
in shooting galleries [2,32,148,150], and thus conducive
for infection transmission. In Pakistan, speciﬁcally, much
of the injecting appears to occur in public places among
groups, and with the reported use of professional injectors
or ‘street doctors’, who frequently re-use injecting equip-
ment [2,32,151–155].
Our results suggest that prisons are a setting predictive
of higher HCV antibody prevalence (Table 3), possibly be-
cause of higher-risk injecting in prisons, or that this setting
tends to be frequented with higher-risk PWID. Other evi-
dence supports this conjecture, and indicated an important
role for incarceration in the dynamics of HCV and HIV
transmission in MENA [9,23,156,157]. This highlights
the need for harm reduction and HCV/HIV testing and
treatment services in prisons.
Genotype 3was found to be themajor circulating strain
among PWID (Table 4), in concordance with the global as-
sociation between injecting drug use and this genotype
[158]. This ﬁnding, however, also reﬂects the fact that
genotype 3 is the dominant circulating strain in
Afghanistan[18,159] and Pakistan [19,159,160], also
with a large presence in Iran [14,159], countries that con-
tributed most of the genotype studies.
Despite the observed high burden of HCV and the
emerging and, at times, large HIVepidemics among PWID
in MENA [9,23,24,32,143,144], harm reduction services
remain overall limited or essentially non-existent across
countries, hindered by poor availability, quality and cover-
age of services, stigma, fear of legal prosecution, ineffective
HCV epidemiology in PWID 11
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governance, limited resources and competing national pri-
orities. By 2016, needle and syringe exchange programs
(NSPs) were available only in 10 countries of the region,
and opioid substitution therapy (OST) in only ﬁve [161].
Such programs, when they attain high coverage, have
proved successful in reducing both HCVand HIV incidence
in other regions [162–164].
Within the socio-cultural and politico-legal context of
the region, and with the overall reluctance of political
leaders to acknowledge and deal with most affected com-
munities, harm reduction in MENA is still the realm of
non-governmental organizations (NGOs). Experience in
several countries such as Morocco, Iran, and Lebanon,
among others, has proved that this is a successful and fea-
sible model to access and reach hard-to-reach communi-
ties such as PWID [23,165]. Scale-up of harm reduction
and further integration of NGO services within national
policies are needed to strengthen the response to the high
burden of HCV and the growing burden of HIV among
PWID inMENA. Recent evidence has emphasized the effec-
tiveness of HCV DAA treatment as prevention (HCV-TasP)
in achieving HCV elimination by 2030 [166,167], even
in countries with very large epidemics such as Egypt and
Pakistan [12,13,19,160,167,168]. Essentially, HCV-TasP
effectively reduces the pool of HCV chronically infected in-
dividuals, thereby curtailing the onward transmission of
the infection. Several countries, most prominently Egypt
[169,170], have initiated and implemented ambitious
and large DAA treatment programs to achieve elimination
[171]. Evidence has highlighted the potency of combining
HCV-TasP, which reduces the prevalence of chronic infec-
tion and onward transmission, with harm reduction
services, such as NSP and OST programs, which reduce
HCV incidence [167,172]. Integrating HCV testing and
treatment in harm reduction services is integral to over-
coming difﬁculties in accessing PWID for HCV interven-
tions and to effectively reduce the number of chronically
infected PWID.
A review of HCV, HBV and HIV among PWID globally
has been recently published, in which the reported HCV
antibody prevalence among PWID (48.1%) was similar
to that found in this study (49.3%) [8]. However, as a
consequence of our comprehensive systematic approach,
including searches of national journals and databases
and the gray literature, this study identiﬁed more data for
MENA, covered more countries for this region, analytically
examined trends and associations and reported more
outcome measures and analyses (such as for genotype
distribution).
This study identiﬁed key gaps in the epidemiological ev-
idence for HCV infection among PWID in MENA. Evidence
varied substantially by country, with no studies identiﬁed
for 12 of the 24 MENA countries (Table 1). Several coun-
tries that reported high HCV antibody prevalence also
had too few available studies, such as for Libya, with only
one identiﬁed study (of high quality), but at a very high
antibody prevalence of 94.2% [110]. Some studies were
limited to a single metropolitan area or study site, and
therefore may not be representative of the wider
PWID population in the country. Indeed, from countries
where there was a high number of studies, such as Iran
(Table 1), there was wide variation in antibody prevalence,
suggesting the possibility of bias in estimating country-
speciﬁc antibody prevalence for countries with too few
studies.
Only seven studies reported HCV RNA among
antibody-positive PWID. Accordingly, the estimated vire-
mic rate may not be representative of the wider PWID pop-
ulation in the region. However, a systematic meta-analysis
of viremic rates in different populations inMENA arrived at
similar values for the viremic rate, irrespective of subregion
or population [30]. Similar values were also reached in the
probability-based and nationally representative surveys in
Egypt [173,174], in the National Health and Nutrition Ex-
amination Surveys in the United States [175] and in other
population-based surveys such as in India [176], Ireland
[177] and Latvia [178].
Only 15 studies reported HCV genotypes among PWID,
and therefore available genotype data may not have cap-
tured the true genotype distribution and diversity in PWID.
For example, the HCV epidemic in Egypt [12,13,167], the
largest in MENA, is very dominated by genotype 4 [159],
but there were few studies from Egypt for PWID, thus pos-
sibly underestimating the frequency of this genotype in all
of PWID in MENA.
Most studies employed non-probability-based sampling;
however, the results of the meta-regression indicated that
this had no discernable effect on observed HCV antibody
prevalence (Table 3)—this may not have limited the repre-
sentativeness of these studies. High heterogeneity in anti-
body prevalence was observed (Table 2), but most of it
remained unexplained by the considered factors in the
meta-regressions (Table 3). As indicated above, we were
unable to assess the number of chronically infected
ex-PWID, as available studies investigated only current
PWID—our estimate for the number of chronically in-
fected PWID represents the lower bound.
Despite these limitations, we were able to identify a sub-
stantial volume of evidence on HCV infection in PWID in
MENA, which facilitated diverse analyses leading to infor-
mative inferences. However, further research is needed to
address the gaps in evidence. Expanding existing surveil-
lance systems and conducting repeated integrated
bio-behavioral surveillance (IBBS) surveys for HCV (and
HIV) in PWID is critical in delineating HCV epidemiology
in this population in countries with limited or no data
[2,143,179]. These surveys need also to have a wider
geographic coverage with multi-sites included, and must
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incorporate innovative sampling methodologies, such as
respondent-driven sampling or time-location sampling, to
reach PWID populations. PWID size estimation studies
and mapping is also critical in delineating the typologies
of PWID injecting and sexual networks [32]. More studies
of HCV viremic rate are also warranted, especially so that
the viremic rate could be used to monitor the progress in
scaling-up HCV treatment [30]. Addressing these gaps is
critical to inform the expansion of harm reduction services
and testing and treatment programs.
CONCLUSION
Our ﬁndings indicated high HCV antibody prevalence
among PWID in MENA, approximately half of whom have
ever been infected with this infection and one-third are
chronically infected. There was no evidence for any decline
in antibody prevalence in recent years. Most infections
among PWID were either by genotypes 3 or 1. In addition
to 221000 chronically infected current PWID, there is an
unknown number of ex-PWIDwhomay have acquired the
infection during their past injecting drug use.
The evidence collectively, and overwhelmingly, attests
to the immediate need for a robust response to the epidemic
among PWID. The lack of evidence of a decline in antibody
prevalence and the high viremic rate emphasize that inter-
ventions are either non-existent or have not reached sufﬁ-
cient effectiveness, coverage and/or quality to impact the
epidemiology. Without an appropriate response, elimina-
tion of HCV by 2030 may not be possible. Harm reduction
and testing and treatment services must be expanded in
the wider PWID community as well as in prisons, and in-
novative strategies need to be employed to ensure accessi-
bility to HCV testing and treatment and to offset decades
of stigma and criminalization of this population.
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